Worldwide Humulin sales increased 8 percent in the third quarter of 2013, to $307.0 million. U.S. sales increased 22 percent to $161.4 million, driven by higher prices and, to a lesser extent, higher volume. Sales outside the U.S. decreased 5 percent, to $145.6 million, driven by decreased volume and the unfavorable impact of foreign exchange rates, partially offset by higher prices.
Third-quarter 2013 sales of Forteo were $306.7 million, a 6 percent increase compared with the third quarter of 2012. U.S. sales of Forteo were relatively flat at $127.9 million, as higher prices were offset by lower volume. Sales outside the U.S. increased 11 percent, to $178.8 million, due to increased volume, primarily in Japan, partially offset by the unfavorable impact of foreign exchange rates.
In the third quarter of 2013, Zyprexa sales totaled $278.7 million, a decrease of 26 percent compared with the third quarter of 2012 due to the loss of patent exclusivity in 2011 in the U.S. and most major international markets outside of Japan. U.S. sales of Zyprexa decreased 51 percent to $32.9 million. Zyprexa sales in international markets decreased 20 percent, to $245.8 million. Zyprexa sales in Japan were approximately $120 million and were negatively impacted by the continued weakness of the Japanese yen.
Evista sales for the third quarter of 2013 increased 3 percent to $255.3 million. U.S. sales of Evista increased 14 percent to $191.8 million, driven by higher prices, partially offset by lower demand. Sales outside the U.S. decreased 19 percent to $63.5 million, driven by the unfavorable impact of foreign exchange rates and lower prices, partially offset by higher volume in Japan.
During the third quarter of 2013, Strattera generate
|SOURCE Eli Lilly and Company|
Copyright©2012 PR Newswire.
All rights reserved